A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

drug protocol number

CLOU064C123

drug sponsor

Novartis

drug study

remibrutinib

drug trial site

King Faisal Specialist Hospital and Research Center (Jeddah) - King Abdulaziz Medical City NG (Jeddah) - King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase